PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

"Some of the most recent trends in pharmaceutical innovation have been fueled by the FDA, which is providing significant incentives to companies, including the 2012 inception of the “breakthrough therapy” designation, which helps accelerate the approval process for drugs addressing significant unmet needs. Ten breakthrough therapies were launched last year."

Pain, an unmet need... And FDA ODD for pancreatic cancer... I see a potential blockbuster therapy here...

"Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech’s treatment in (i) reducing the severe pain that occurs in patients with advanced pancreatic cancer; and (ii) slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen."

"Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this – particularly in the case of advanced cancers.” Ken Waggoner

"...we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future." Ken Waggoner

http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/

http://www.pharmacytebiotech.com/pharmacyte-biotechs-expanded-follow-study-malignant-ascites-fluid-accumulation-final-stages-preparation/

http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/

http://www.forbes.com/sites/arleneweintraub/2015/04/14/growth-in-drug-spend-hits-13-year-high-note-to-pharma-innovation-pays/?utm_campaign=yahootix&partner=yahootix